The most severe form of autosomal dominant polycystic kidney disease occurs in patients with mutations in the gene (PKD1) encoding polycystin-1 (PC1). PC1 is a complex polytopic membrane protein expressed in cilia that undergoes autoproteolytic cleavage at a G protein-coupled receptor proteolytic site (GPS). A quarter of PKD1 mutations are missense variants, though it is not clear how these mutations promote disease. Here, we established a cell-based system to evaluate these mutations and determined that GPS cleavage is required for PC1 trafficking to cilia. A common feature among a subset of pathogenic missense mutations is a resulting failure of PC1 to traffic to cilia regardless of GPS cleavage. The application of our system also identified a missense mutation in the gene encoding polycystin-2 (PC2) that prevented this protein from properly trafficking to cilia. Using a Pkd1-BAC recombineering approach, we developed murine models to study the effects of these mutations and confirmed that only the cleaved form of PC1 exits the ER and can rescue the embryonically lethal Pkd1-null mutation. Additionally, steady-state expression levels of the intramembranous COOH-terminal fragment of cleaved PC1 required an intact interaction with PC2. The results of this study demonstrate that PC1 trafficking and expression require GPS cleavage and PC2 interaction, respectively, and provide a framework for functional assays to categorize the effects of missense mutations in […] Research Article Nephrology
Introduction
The most common and severe form of autosomal dominant poly cystic kidney disease (ADPKD) results from mutations in PKD1. PKD1 encodes human polycystin1 (PC1), a large, complex, low abundance polytopic membrane protein with structural features suggestive of a cellsurface receptor (1) . PC1 is the common ratelimiting component of the ADPKD signaling pathway, and functional dosage of the gene also modulates the phenotypes in isolated autosomal dominant polycystic liver disease and autoso mal recessive polycystic kidney disease (2) . Mutations in PKD2, encoding human polycystin2 (PC2), cause ADPKD with an iden tical, albeit milder, phenotypic spectrum compared with that of PKD1. PC2 is a member of the transient receptor potential (TRP) family of cation channels. Biochemical evidence shows that PC1 and PC2 interact directly (3, 4) , and genetic and phenotypic evidence suggests that they act in a common pathway (2, (5) (6) (7) . The prevailing hypothesis is that PC1 and PC2 form a receptor channel complex with either mechanical or ligand stimuli as the upstream signals (8) (9) (10) (11) , although direct evidence for this func tional interrelationship is lacking. Coassembly with PC1 has been proposed as a requirement for trafficking of PC2 to the cell surface (12) , although PC2 can traffic to cilia independently of PC1 (13) . There is also evidence for divergent functions for PC1 and PC2: e.g., PC2 is involved in leftright axis determination (14) (15) (16) and
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Ca
2+ homeostasis in the ER (17, 18) , whereas PC1 can be expressed in association with the lateral membrane (19) (20) (21) , adherens junc tions (22) , and desmosomes (23) .
Several lines of evidence have led to the emergence of the pri mary cilium as the central cellular compartment in the pathogen esis of cystic kidney diseases (24) . PC1 and PC2 are expressed in the membrane overlying the primary cilium (25, 26) . The majority of gene products associated with fibrocystic kidney diseases other than ADPKD are also expressed in the ciliabasal body complex (24, 27) . A forward genetic screen in zebrafish based on the cystic pronephros phenotype identified a number of ciliarelated proteins as well as PC2 (28) . Fibrocystic disease-associated gene products, including PC2, are associated with other known cilial phenotypes such as leftright axis defects (14) (15) (16) . In addition, the role of cilia in cyst formation was tested prospectively by showing that disrup tion of cilia through selective inactivation of Kif3a or intraflagellar transport proteins in the kidney results in cyst formation (29) (30) (31) . Recently, we have found that cyst formation following inactiva tion of PC1 or PC2 is markedly slowed by concomitant removal of structurally intact cilia, suggesting that intact cilia devoid of poly cystins are the primary driving force in the progression of ADPKD (32) . Despite these cogent arguments, direct evidence for the pre cise mechanism of PC1 and PC2 action in cilia has been elusive.
Human PC1 is composed of 4,302 amino acids with approxi mately 3,000 amino acid extracellular NH 2 termini, 11 transmem brane domains (33) , and approximately 220 amino acid cytosolic COOH termini. The extracellular NH 2 terminal domain contains a distinct combination of protein motifs including immunoglobulin Altered trafficking and stability of polycystins underlie polycystic kidney disease Yiqiang Cai, 1 Sorin V. Fedeles, 1 Ke Dong, 1 Georgia Anyatonwu, 2 Tamehito Onoe, 1 Michihiro Mitobe, 1 Jian-Dong Gao, tideNglycosidase F (PNGase F) removes all Nglycan moieties. An absence of endo H resistance in PC1-FL shows that uncleaved PC1 is not present on the cell surface. AntiFLAG immunoprecipitation (IP) of PC1-NTF only coimmunoprecipitated the intracellular endo Hsensitive fraction of PC1-CTF ( Figure 1C ). The failure to detect the cellsurface pool of PC1-NTF was likely due to shedding of the surfaceexpressed PC1-NTF into the culture medium (ref. 41 and Figure 1D ). We further examined the surface location of PC1 bio chemically by selective biotinylation of the apical and basolateral compartments in nonpermeabilized, polarized LLC-PK 1 cells grown on filter inserts (51) . We found that PC1-CTF was strongly biotiny lated on the apical surface of cells, but was virtually absent from the basolateral surface ( Figure 1E ). Uncleaved PC1-FL was not detected by cellsurface biotinylation in live cells ( Figure 1E ). We next deter mined whether the absence of PC1-FL from the cell surface was indicative of very efficient cleavage of PC1 during trafficking or an intrinsic property of uncleaved PC1. The cleavagedeficient mutant PC1 L3040H bearing an amino acid substitution at the consensus GPS HL 3040 ↓T of the mouse sequence remained completely endo H sensitive, indicating that the uncleaved protein cannot reach the cell surface ( Figure 1F ). The fact that PC1-CTF acquired endo H resistance suggests that its path to the cell surface passes through the Golgi apparatus. The biotinylation pattern in polarized epithe lial cells shows that in the steady state, PC1-CTF is preferentially expressed on the apical surface in at least some cell types.
Truncation mutations and cilia trafficking of PC1. The site of expression of PC1 on the apical surface most relevant to the pathogenesis of ADPKD is the primary cilium. We investigated the structural elements of PC1 that are critical to cilia trafficking. We hypothesized that defective trafficking of PC1 to cilia would serve as an in vitro functional test for a subset of putative patho genic variants in Pkd1. For the purposes of this study, all human PC1 sequence variants were introduced into the equivalent codon in mouse Pkd1 cDNA to achieve the same amino acid substitution. The variants are described using mouse sequence nomenclature and mousetohuman amino acid equivalencies, and the patho genic potential for all variants are presented in Supplemental Table 1 (supplemental material available online with this article;  doi: 10.1172/JCI67273DS1). PC1 was detected in cilia by immun ofluorescence (IF) cell staining using COOH or NH 2 terminal epitopes independently in a variety of cell lines including previ ously reported mouse embryonic fibroblast (MEFs) (2), LLC-PK 1 cells (Figure 2A) , and IMCD3 and MDCK cells (data not shown). The HA and FLAG epitopes colocalized in cilia, indicating that both PC1-CTF and PC1-NTF appeared in cilia together ( Figure  2A ). We observed PC1 expression along the entire axoneme of the cilia, and PC1 did not colocalize with basal bodies marked by γtubulin ( Figure 2, A and B) . The cleavagedeficient PC1
L3040H
was not detectable in cilia axonemes or at the basal bodies despite robust expression in the cell body, showing that GPS cleavagede ficient PC1 carrying this specific GPS motif variant did not traffic to cilia ( Figure 2C ). These findings imply that the HA and FLAG epitopes are detecting cleaved PC1-CTF and PC1-NTF, respec tively, as the only forms of PC1 in cilia.
Between 65% and 75% of pathogenic mutations in PKD1 are either nonsense, splice site, or insertion/deletion changes that are predicted to result in premature termination of the PC1 pep like PKD repeats (34) (35) (36) , a receptor egg jelly (REJ) domain (37) that includes fibronectin type III repeats (38) and is part of a recently identified structural GAIN domain (39) . The REJ/GAIN domain is required for autoproteolytic cleavage of PC1 at a G protein-cou pled receptor proteolytic site (GPS) sequence, HL↓T 3049 (40) , that yields an extracellular NH 2 terminal fragment (PC1-NTF) and an intramembranous COOHterminal fragment (PC1-CTF) (39, 41, 42) . PC1-NTF and PC1-CTF remain noncovalently associated with each other. The conservation of the GPS in all PC1 homologs (43) suggests functional importance; although at least 2 homologs, PKDREJ and SuREJ2, do not undergo GPS cleavage (44, 45) .
Cysts in ADPKD are thought to occur primarily by a cellular recessive 2hit mechanism, with the majority of clinically signifi cant heterozygous germline mutations in PKD1 and PKD2 result ing in loss of function. Nonetheless, approximately 25% of the presumed pathogenic variants in PC1 are predicted to result in nonsynonymous amino acid substitution mutations (46) . Increas ing evidence shows that a significant proportion of these nonsyn onymous substitution variants are functionally hypomorphic and have a milder clinical presentation compared with that of com plete lossoffunction variants (47, 48) . The pathogenic effects of such variants have proven difficult to assess experimentally in the absence of robust functional assays for PC1. In the current study, we examined the functional expression and ciliatrafficking prop erties of mutant forms of murine PC1 and human PC2 in vitro and of PC1 in vivo. We found that a subset of pathogenic amino acid substitution mutations in PC1 and PC2, as well as mutations affect ing GPS cleavage in PC1, result in failure of polycystins to traffic to cilia. To extend these cellbased studies to mammalian tissues in vivo, we modified a Pkd1 BAC transgene that can fully rescue the embryonically lethal Pkd1 -/-phenotype with a mutation to abrogate GPS cleavage and showed that this mutation results in a complete lossoffunction allele that can no longer rescue any part of the Pkd1 -/-phenotype. We used the BAC transgenic models to establish that there are significant differences in the subcellular compart ment distributions of PC1 and murine PC2 in tissues, supporting the hypothesis that these proteins may also have functions inde pendent of each other. Finally, we examined PC1 expression in the absence of PC2 and found that interaction with PC2 is required to maintain steadystate expression levels of PC1-CTF. These studies highlight the role of defective polycystin trafficking and expression in all forms of ADPKD and suggest a role for therapies directed at these processes in a selected subset of ADPKD patients.
Results
Asparagine-linked glycosylation and apical expression of PC1. Full length mouse PC1 (PC1-FL) with NH 2 and COOHterminal epitope tags (49) cleaved at the GPS site to yield the HA epitopetagged PC1-CTF and the FLAG epitope-tagged PC1-NTF, which remained noncovalently associated with each other (ref. 41 and Figure 1A ). We examined the asparaginelinked glycosylation (Nglycosylation) pattern of PC1. PC1-CTF showed both endo glycosidase H-resistant (endo H-resistant) and -sensitive forms, whereas the fulllength, uncleaved PC1 protein PC1-FL was entirely endo H sensitive ( Figure 1 , B and C, and ref. 50) . Endo H resistance defines the fraction of PC1-CTF that traffics past the middle Golgi apparatus to the cell surface. Digestion with pep both HA and FLAG epitope detection ( Figure 2 , I and J). The trun cation mutant lacking the entire COOH terminus PC1 Y4100X failed to reach cilia when detected by either epitope (Figure 2 , K and L) despite stable expression of the protein product and GPS cleavage ( Figure 2D ). In keeping with this failure to traffic to cilia, PC1 Y4100X CTF did not acquire endo H resistance ( Figure 2D ). These data indicate that the region between Y4100 and R4204 is necessary for trafficking of PC1 to cilia, that interaction with PC2 is not required for GPS cleavage or cilia trafficking of PC1, and that GPS cleavage is not sufficient for cilia trafficking of PC1.
Missense mutations and cilia trafficking of PC1. The remain ing 25% to 35% of pathogenic PKD1 mutations are predicted to result in nonsynonymous amino acid substitutions. To date, there have been no systematic in vitro assays to assess the pathogenic ity of these variants. This has made the functional assessment of diseasecausing missense mutations challenging. We evalu tide chain (46, 48) . We determined the effect of such mutations in cilia trafficking of PC1. We selected the naturally occurring human mutation PC1 R4228X (mouse equivalent, PC1 R4218X ), which has been shown to abrogate interaction with PC2 (12) . In addition, we engi neered 2 experimental truncations, PC1 R4204X and PC1 Y4100X , based on the mouse sequence. The former truncates PC1 before the coiledcoil domain required for interaction with PC2 (52, 53) ; the latter deletes the entire predicted cytoplasmic COOH terminus (33) . All 3 truncation mutants showed normal cleavage at the GPS when stably expressed in LLC-PK 1 epithelial cells ( Figure 2D ). The PC1 R4218X mouse equivalent of the human pathogenic mutant was detectable in cilia by both the COOHterminal HA epitope and the NH 2 terminal FLAG epitope ( Figure 2 , E and F). We confirmed the specificity of these findings by colabeling with γtubulin to detect basal bodies and avoid possible crossreactivity along the axon eme ( Figure 2, G and H) . PC1
R4204X similarly appeared in cilia by Figure 1 ). These data show that pathogenic amino acid substitution mutations in PC1 can abrogate cilia trafficking independently of GPS cleavage and support the hypothesis that cilia trafficking is an effective in vitro surrogate assay for a subset of pathogenic PC1 mutations. We next determined whether amino acid substitution muta tions affect other functions of PC1 besides GPS cleavage and traf ficking to cilia. PKD domains were first identified in the extracel lular region of PC1 (34-36) and were proposed to have possible ligandbinding functions (54) . The PKD domains have a βsand wich fold, also called an Iglike fold, among which a WDFGDGS motif is the most conserved sequence (54) . We examined a puta tive "likely" pathogenic human mutation, PC1 G1166S (Supplemen tal (54) . The mouseequivalent PC1 G1160S mutant is a stable protein product that was cleaved at the GPS ( Figure 3A ) and was expressed abundantly in cilia ( Figure 3F ). If this variant is indeed pathogenic, as suggested by sequence conservation and structural data (54) , these findings suggest that functions other than GPS cleavage and cilia trafficking, perhaps involving ligand interactions, may also be disrupted in pathogenic amino acid sub stitution mutations in PC1.
Missense mutations and cilia trafficking of PC2. Although mis sense variants are less common in PKD2 (~6%-14%), we took this opportunity to evaluate whether ciliatrafficking mutations also play a role in ADPKD resulting from mutations in PKD2. We evaluated PC2
W414G
, a mutation in the highly conserved polycystin domain (55) common to both PC1 and PC2 and located in the large extracellular loop between the first and second transmembrane segments of PC2 and the sixth and seventh transmembrane seg ments of PC1 (43) . Singlechannel recordings using bilayers made with ERenriched vesicles from LLC-PK 1 cells stably expressing PC2 W414G showed that the mutation did not abrogate channel activ ity of PC2 in the ER ( Figure 4 , A and B). The calcium concentra tion on the cytoplasmic side needed to maintain the open proba bility near approximately 50% was the same for both the WT and PC2 W414G channel, suggesting that there were no obvious differ ences in the open probability between the WT and mutant chan nels. At higher holding potentials, the currents through PC2 W414G showed a lower conductance than did the currents through the WT channel, but at the lower holding potentials, which were more representative of the ER membrane, the channel conductances were similar for the WT and PC2 W414G mutant. In aggregate, it is unlikely that the differences in channel activity account for the pathogenicity of PC2 W414G .
PC2
W414G did not traffic to cilia despite robust expression in cells, suggesting this to be the more likely mechanism for its pathogenesis ( Figure 4C ). As a positive control, a channeldead pathogenic missense variant, PC2 D511V (17, 56) , trafficked to cilia in the same cell type ( Figure 4D ). We further confirmed the spec ificity of the ciliatrafficking defect in PC2 W414G by introducing the mutation into the truncated PC2 L703X backbone that normally shows particularly robust trafficking to cilia ( Figure 4E and ref. 13 ). The truncated protein containing the point mutation PC2
W414G;L703X did not traffic to cilia ( Figure 4F ). The data suggest that cilia traf ficking mutants occur in PC2, that the conserved extracellular domain unique to polycystins is important in trafficking of PC2, ated a series of human pathogenic missense variants in an effort to categorize their functional consequences by in vitro assays of cilia trafficking. We first determined whether naturally occurring mutations that impair GPS cleavage also abrogate cilia traffick ing of PC1. A previous study had shown that 2 human mutations remote from the actual G protein-coupled proteolytic cleavage sites, PC1
E2771K and PC1
F2853S
, respectively corresponding to mouse codons PC1 E2766 and PC1
F2848
, abrogate GPS cleavage (41) . These mutations, originally referred to as REJ mutations, occur in the GAIN domain recently defined by structural studies as being required for autoproteolytic cleavage at the GPS (39) . For the current study, we selected another human mutation, PC1 L2816P , corresponding to mouse PC1 L2811P , which is located in the GAIN domain between PC1 E2771K and PC1 F2853S and is considered likely to be pathogenic (Supplemental Table 1 ). PC1 L2811P did not cleave at the GPS ( Figure 3A ) and did not localize to cilia ( Figure 3B ). As a positive control for the assay technique, the variant PC1 C2085R that changes a nonconserved residue in the fifteenth PKD domain in the mouse sequence (PC1 C2085 ) to the equivalent amino acid from the human sequence (PC1 R2089 ) was cleaved normally at the GPS ( Figure 3A ) and trafficked normally to cilia ( Figure 3C ). The find ing that 2 independent mutations, PC1 L3040H and PC1
L2811P
, which result in loss of GPS cleavage, also failed to traffic to cilia is consis tent with the hypothesis that GPS cleavage is required for traffick ing of PC1 to cilia.
We next investigated whether ciliatrafficking defects were a feature of amino acid substitution mutations in the extracellular domain of PC1, irrespective of their effects on GPS cleavage. We selected a pair of human mutations, PC1
C210G and PC1
V690D
, outside the GAIN domain region that were predicted to be pathogenic (Sup plemental Table 1 ). PC1 C210G alters a highly conserved cysteine in the WSC domain. PC1
V690D is in the interdomain region between the Clectin and PKD domains. We produced the corresponding mouse variants, PC1 C210G and PC1
V685D
. PC1 C210G and PC1 V685D cleaved nor mally at the GPS ( Figure 3A ). Despite normal GPS cleavage and robust expression in the cell body, PC1
C210G and PC1 V685D failed to , truncating the entire COOH terminus, was not expressed in cilia. The COOH terminus of PC1 was detected with anti-HA (E, G, I, K, and L), and the NH 2 terminus was detected with anti-FLAG (F, H, and J). Cilia axonemes were marked by anti-acetylated tubulin (E, F, I, J, and K), and basal bodies were marked by anti-γ-tubulin (G, H, and L). The rightmost panel for each series of images in A-C and E-L represents a merge of the images at left. Scale bars: 5 μm.
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jci.org Volume 124 Number 12 December 2014 that cilia location is critical to PC2 function in ADPKD, and that channel activity in the ER without cilia location is not sufficient to avoid polycystic disease. Bacterial artificial chromosome transgenic models of PC1 expression. PC1 is a complex, lowabundance protein that has been diffi cult to evaluate by in vivo studies, yet such studies are essential for validating and extending findings based on cell line and other in vitro approaches. We therefore established and validated a model system based on modification ("recombineering") of bacterial artificial chromosomes (BACs) by homologous recombination in E. coli, followed by the generation of transgenic mouse lines expressing these modified BACs to evaluate the properties of PC1 in vivo (2, 57-59). This approach allows for targeting of a single allele more than once in a manner that is not available in knockin models, while still providing high fidelity to native gene expression patterns in a copy number-dependent, inte gration site-independent manner. We initially modified the mouse BAC clone RPCI22-287A3 containing Pkd1 by inserting a tripleFLAG epitope after the NH 2 terminal leader sequence and a tripleHA epitope before the stop codon in the same locations as in the Pkd1 cDNA (2, 49) . BAC clone RPCI22-287A3 contains 7 other genes in their entirety as well as parts of 2 additional genes (Supple mental Table 2 ). Seven transgenic founder lines produced with this modified Pkd1 F/H -BAC transgene gave germline transmission; 4 of these lines were analyzed further (Fig  ure 5 and Supplemental Tables 3 and 4) .
BACs typically yield low copy number transgenic insertions, and our founders had 1-8 copies of the BAC transgene as determined by quantitative PCR (qPCR) (Supplemental Table 3 ). We found that PC1 protein expres sion determined by semiquantitative immunoblotting (IB) was approximately 2 to 4fold higher relative to PC1 expressed in the singlecopy founder Tg14 ( Figure 5 , A and B, and Supplemental Table 3 ). PC1 expression correlated with the transgene copy number in 3 of the 4 founders. It is likely that the 8 "copies" of the BAC detected by qPCR in Tg8 included some BAC inserts that were disrupted in the integration process, so that only a subset of the BAC inserts actu ally expressed PC1. The distinct nature of the respective modifica tions in the Pkd1 F/H -BAC transgene and the native Pkd1null allele enabled us to distinguish null, WT, and BAC alleles for purposes of genotyping (Supplemental Figure 2) . All 4 founder lines were able to rescue the embryonic lethality when combined with the Pkd1 -/-background (Supplemental Table 4 and ref. 2) , indicating that the BAC transgene was effective in producing a functional protein independently of the integration site and copy number and that the epitope tags did not impact in vivo function of PC1. High-copy number Pkd1 transgenes have been associated with kidney cyst for mation (60, 61). We did not observe cyst formation in our low-copy number BAC transgenic models, nor were any other abnormal phe ) did not affect GPS cleavage of PC1. The GAIN/REJ mutant PC1 L2811P abrogated GPS cleavage, whereas the benign polymorphism PC1 C2085R had no effect. Cell lysates were subjected to IP and IB with anti-HA. Each panel was run on a separate gel. (B-F) Cilia trafficking of the PC1 variants in A. Pathogenic mutants in the REJ/GAIN domain (B) or NH 2 terminus (D and E) of PC1 did not traffic to cilia, whereas a pathogenic mutant in the fifth PKD domain (F) trafficked to cilia similarly to WT protein. (C) The nonpathogenic variant was expressed in cilia. PC1 variants were expressed in LLC-PK 1 cells and IF performed using anti-acetylated α-tubulin (red) and anti-FLAG (green) antibodies. Arrows show cilia in x-y images; inserts are 3D reconstructions from z-stacks that have been rotated to show cilia above the plane of the cell bodies and were used to verify that cell bodies belonging to the respective cilia were expressing PC1 variants (green). Original magnification (inserts), ×2. The rightmost panel for each series of images B-F represents a merge of the images at left. Scale bars: 5 μm. -BAC transgene was expressed most strongly in membraneenriched fractions from lung tissue, while kidney and heart showed moderate expression ( Figure 5D ). PC1 expression in other tissues was difficult to detect by IB of membraneenriched fractions (Fig  ure 5D, left panel) ; expression in these tissues was detectable by IP followed by IB and longer exposures ( Figure 5D , right panel). It is also notable that PC1 expression has been reported to be downregulated soon after birth (63, 64) . Consistent with this, we found that detection of PC1 expression was markedly reduced in mice after 2 weeks of age (data not shown). The patterns of expression we observed were reproduced among several transgenic lines (data not shown), showing that BAC transgenic expression of PC1 is indeed faithful to the native protein pattern of expression.
The BAC transgenic lines showed that the overall abun dance of PC1 in all tissues was very low. Even using anti epitope antibodies required either enrichment of membrane fractions in tissue lysates ( Figure 5 , A-D) or IP followed by IB ( Figure 5D ) to reliably detect the protein in native tissues. As a consequence of this low abundance, we were unable to reli ably detect PC1 in native tissue immunohistochemistry. We therefore prepared MEFs from Pkd1 F/H -BAC transgenic and nontransgenic mice and confirmed expression and GPS cleav age of PC1 in the MEFs ( Figure 5E ). We were able to detect the epitopetagged PC1 in cilia of MEFs, confirming expression of the transgeneencoded protein in cilia ( Figure 5F and ref. 2) . The data support the conclusion that modified BAC transgenic lines are an effective model for studying PC1 in vivo.
Effects of PC1 mutations in native tissues. The dualepitopetagged Pkd1 , introducing the PC2 W414G mutation on the PC2 L703X backbone, completely abrogated cilia location despite stable expression of the protein product. The rightmost panel for each series of images in C-F represents a merge of the images at left. Scale bars: 5 μm. fl/fl Ksp-Cre mice, which developed cysts in the medullary thick ascending loop of Henle (mTAL), the dis tal convoluted tubule (DCT), and the collecting duct ( Figure 6D and ref. 65) . We found that the same was true in Pkd1 fl/fl Pkhd1-Cre mice, in which the cysts were confined to the collecting duct (Fig  ure 6E) . IP followed by IB of cystic tissue lysates from both mod els documented expression of the PC1 L3040H protein (Figure 6 , F and G). In aggregate, these data indicate complete loss of PC1 function in GPS cleavage-deficient PC1 L3040H in vivo. Aberrant trafficking and distinct pools of polycystins in native tissues. We took advantage of the epitopetagged BAC transgenic models to examine the trafficking properties of WT PC1 and the mutant PC1 L3040H in vivo. PC1-CTF from WT Pkd1
F/H -BAC trans genic brain tissue showed endo H-resistant and -sensitive forms in vivo ( Figure 7A ). Uncleaved PC1-FL and PC1
L3040H were com pletely sensitive to endo H (data not shown). For tissue fraction ation studies, we used lung tissue, because it showed the most robust expression of both forms of PC1 by IB ( Figure 5D and Tg9 L3040H ) had 1 copy of the BAC transgene by genomic qPCR, whereas the third line (Tg7 L3040H ) had 3 copies (Supplemental Table  5 ). All 3 transgenic lines showed normal histology at 6 months on a WT background, with no evidence of microscopic cysts in the kidney, liver, or pancreas (data not shown). PC1 expressed from Pkd1
L3040H
-BAC appeared as a single band migrating as PC1-FL without evidence of cleavage at the GPS ( Figure 6A ). The tissue pattern of expression was similar to that of WT Pkd1 F/H -BAC (Fig  ure 6B) . PC1
L3040H retained the capacity to interact with PC2, as evidenced by cellbased cotransfection, coIP studies (Supple mental Figure 4) . None of the Pkd1 L3040H -BAC transgenic lines were able to rescue the embryonic lethality of the Pkd1 -/-mice ( Figure 6C and Supplemental Table 5 ), indicating a complete lossoffunction allele based on a single codon change in the entire BAC insert sequence that included Pkd1 and the other "pas senger" genes. We evaluated the ability of Pkd1
-BAC trans genic lines to specifically rescue the cystic phenotype following . In tissue, fulllength, uncleaved WT PC1 or cleav agedeficient mutant PC1 L3040H remained in the ER compartment, while the cleaved PC1 products trafficked to the cell surface.
We had previously shown that endogenous PC2 distributes pri marily in fractions associated with ER membranes in native kidney tissues (17) . We took advantage of the lineargradient fractiona tion of tissue from the Pkd1-BAC transgenic mice to examine the relative distributions of PC1 and PC2 in tissue ( Figure 7 , B and C). The fractions in which PC2 was most abundant were largely devoid of PC1-CTF and PC1-NTF; conversely, PC1-CTF and PC1-NTF appeared predominantly in fractions that contained only a minor ity of tissue PC2 ( Figure 7B ). The tissue distribution of PC2 did not change with PC1 L3040H expression ( Figure 7C ), consistent with our previous finding that PC2 traffics independently of PC1 (13) . The relatively disparate tissue distribution of PC1 and PC2 supports previous data that PC2 functions as an ER channel independently of PC1 (17, 18) and that PC2 has functions independent of PC1 (15, ure 6B). We fractionated lung tissue lysates on iodixanolbased linear density gradients and compared the distribution of PC1 and PC1 L3040H ( Figure 7 , B and C). We found that WT PC1-NTF and PC1-CTF mainly distributed in the lighter membrane fractions at the top of the gradient that were also enriched in NaK-ATPase, a plasma membrane protein ( Figure 7B ). Uncleaved PC1-FL, as well as a small amount of PC1-NTF, but not PC1-CTF, appeared in frac tions enriched for the ER membrane protein calnexin ( Figure 7B ).
Fractionation of tissue from PC1
L3040H transgenic mice showed that the fulllength, uncleaved protein was retained entirely in fractions marked by the ER protein calnexin ( Figure 7C ). PC1 L3040H was absent from fractions most enriched for NaK-ATPase ( Figure  7C ). We confirmed that the product detected by antiFLAG in the PC1 L3040H transgenic line was a fulllength protein by running it alongside fractions from the WT PC1 gradient ( Figure 7D ). The data show in vivo fractionation of functional PC1 and the disrupted subcellular distribution in tissue of a lossoffunction mutant ) polycystic mice at P15 showing that expression of the uncleaved protein was present in the cystic kidney tissues despite a failure to rescue the PKD. PC1 L3040H was detected by IP and IB with anti-HA. Panels represent noncontiguous lanes from a single gel. -BAC transgenic inser tion, expression of the epitopetagged PC1 protein is expected to be constant between cell lines. We found that the steadystate expression levels of PC1-CTF in Pkd2
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-/-cells were markedly reduced compared with those in Pkd2 fl/fl cells that still express PC2 (Fig  ure 8C ). This did not reflect a global decrease in PC1 levels, as there was no change in the steadystate expression of PC1-FL (Figure 8, C and E) . This also did not reflect a decreased efficiency of cleavage at the GPS, as we observed no change in PC1-NTF steadystate expression levels between Pkd2 fl/fl and Pkd2 -/-cells ( Figure 8D ), nor was there a reciprocal increase in PC1-FL in Pkd2 -/-cells ( Figure 8 , C and E). These results suggest that PC2 is not required for GPS cleavage of PC1. To determine whether the decrease in steadystate levels of PC1-CTF was the result of hyperubiquitination and degradation via the proteasome, we treated Pkd2 -/-cells with the irreversible proteasome inhibitor carfilzomib (Supplemental Figure 5) . As a positive control, HIF1α levels were stabilized in the presence of carfilzomib. We observed that PC1-CTF did not increase with carfilzomib treatment, indi 66). The data further suggest that while only a minor proportion of PC2 appears in the same fractions with the PC1-CTF and PC1-NTF, this subfraction may represent the proposed PC1-PC2 functional complex (3, 4, 67) that is important in the pathogenesis of PKD.
PC1-CTF expression levels are markedly reduced in the absence of PC2. Finally, we sought to examine the unresolved question of the impact of inactivation of Pkd2 on PC1 expression. Our obser vation that overexpression of WT PC2, but not the truncated form PC2 L703X , increased the steadystate levels of PC1-CTF (Supple mental Figure 4 ) led us to question what effect the absence of PC2, as occurs in cyst cells in patients, has on PC1. To test this directly and to avoid potentially artefactual results due to high ) (C) mice were fractionated by density-gradient centrifugation on 5% to 25% linear iodi xanol density gradients. Equal volumes of 16 fractions were loaded in each lane: fraction 1 is the top of the gradient; fraction 16 is the bottom. Samples were analyzed by IB with antibodies against FLAG, HA, calnexin, NaK-ATPase, and PC2. Left and right panels represent separate gels. FLAG, HA, calnexin, and NaK-ATPase were detected on the same gels; PC2 was detected on a separate gel, in which fractions 5 and 6 were combined into a single lane. (D) Fractions 1 and 12 from B were run alongside fraction 11 from C and subjected to IB with anti-FLAG to confirm the differential migration of the PC1-NTF bands detected in B and PC1-FL detected in C. Figure 8F ). These data suggest that PC2 interaction is sufficient for stabilizing PC1-CTF, and this latter function does not require the channel activity of PC2. It is noteworthy that the majority (~85%) of PC2 mutations in patients are truncating and expected to abro gate interaction with PC1. These data pose the novel possibility that the pathogenic effect from truncating mutations in PC2 includes a reduced stability of PC1-CTF below a critical threshold and that cyst formation in PKD2 patients results, at least in part, from a reduced functional dosage of PC1, akin to the mechanism for cyst formation in isolated human polycystic liver diseases (2) . The pathogenicity of PC2 D511V in patients further suggests that the channel activity of PC2 is required for functional integrity of the PC1-PC2 complex inde pendently of PC1-CTF levels in preventing ADPKD.
Discussion
Recent data have established the role of PC1 dosage as the ratelimiting determinant of ADPKD and ADPLD severity (2, 47, cating that increased degradation by the proteasome was not the cause of reduced PC1-CTF in the absence of PC2. The decrease in steadystate levels of PC1-CTF appeared to be a unique effect of PC2 on PC1; loss of PC1 had no effect on the steadystate expres sion levels of PC2 (Supplemental Figure 6) . The findings suggest that PC2, which interacts with PC1-CTF, is significantly required to maintain the steadystate stability of PC1-CTF by a mechanism not dependent on the proteasome.
We used lentivirusmediated reexpression of WT and mutant forms of PKD2 in Pkd2 -/-cells to demonstrate the requirement for interaction between PC2 and PC1 to maintain stable PC1-CTF expression. Reexpression of PKD2 in Pkd2 -/-cells successfully res cued stable PC1-CTF expression ( Figure 8E ). Lentivirusmediated reexpression of a truncated form of PC2 (PC2 L703X ) that lacks the domain for interaction with PC1 failed to rescue PC1-CTF expres sion ( Figure 8E ), suggesting that interaction between the 2 poly cystin proteins is required for PC1-CTF stability. A channeldead pathogenic point mutant, PC2
D511V
, which retains the PC1 interaction Aside from conformational changes, we also found that part of the COOH terminus region of PC1 was necessary for traffick ing out of the ER and into cilia. The pathogenic truncation mutant PC1 R4204X entered cilia, indicating that the coiledcoil domain (res idues 4,214-4,248) thought to mediate interaction with PC2 (53, 74) is not required for trafficking PC1 to cilia. Complete deletion of the COOH terminus in PC1 Y4100 shows a novel functional require ment of the region between PC1 Y4100 and PC1 R4204 for PC1 traffick ing. While it is possible that this region is required to maintain conformational integrity to allow trafficking much the way point mutations do, it is more likely that this region of the COOH ter minus is required for interaction with factors that are critical for PC1 egress from the ER. Not all point mutations in PC1 affect cilia trafficking. A mutation in a conserved residue in one PKD domain, PC1
G1160S
, remains competent in GPS cleavage, cilia trafficking, and interaction with PC2, but still lacks normal function. Muta tions in PKD domains may be part of a class of variants deficient in PC1 functions, perhaps related to ligand interaction, which are required once the protein is in cilia. Experimentally, this type of mutation may serve as an appropriate entry point for discovery of the ciliaspecific functions of PC1 (75, 76) -i.e., if a cellular or physiological response is attributed to PC1 specifically in cilia, then expression of these mutants in place of WT protein would be expected to result in loss of the specific response.
While amino acid substitution variants are less common in PC2 and therefore less likely to be targets for therapy, they can nonetheless be instructive in discerning function for the polycys tins. The pathogenic missense variant PC2 D511V has complete loss of channel activity (17) but traffics to cilia, whereas a variant in a highly conserved residue, PC2
W414G
, which has largely preserved channel function, does not traffic to cilia. These data provide sup port for the hypothesis that both cilia location and channel activity in cilia are required for polycystin function (15, 16) . On the other hand, recent data directly examining ciliary calcium suggest that calcium concentrations in cilia are significantly higher than those in the cell body (75, 76) . To put all of these findings together, the hypothesized role of ciliary polycystins in global cellular calcium responses may require significant revision. The aggregate infor mation available suggests a hypothesis that the ciliary calcium channel function of polycystins has very local effects, possibly acting only within the polycystin protein complex. Nonetheless, our findings offer the first opportunity to categorize groups of mis sense mutations in polycystins into functionally distinct subtypes. The groups of variants for both polycystins that do not traffic to cilia may be appropriate to target with therapies aimed at coun tering proteinfolding defects (77) and raise the prospect that such therapies may be applicable to selected patients with ADPKD.
ADPKD is a disease of 3D organ structure manifest in the complex cellular milieu of the adult kidney. As a consequence, the relevance of mechanistic discoveries based on in vitro cell culture models requires validation with in vivo models. To this end, we developed BACrecombineering transgenic models for Pkd1 (2) . BAC transgenic models have practical advantages over conventional knockin models, including the ability to target the same allele multiple times, the speed with which mutant mouse lines can be obtained, and the reduced cost in doing so. The emer gence of genomeediting technologies, specifically the CRSPR/ 68). These findings raise the possibility that targeted personalized therapeutic strategies based on the specific nature of the mutations (69) may be applicable to ADPKD. Success in this approach will require an understanding of the specific functional consequences associated with patient mutations. While the pathogenic princi ples of proteindestructive chainterminating mutations in poly cystins are understood, less is known about the functional effects of nonsynonymous amino acid substitution mutations. These mis sense variants may be the most likely initial targets for mutation specific therapies in ADPKD. Nearly half of the predicted patho genic mutations associated with human Mendelian disorders involve single amino acid substitutions (70) . Loss of normal pro tein folding or trafficking features prominently among missense variants for which the mechanism is known (70) and plays impor tant roles in diseases such as cystic fibrosis, Alzheimer's disease, Parkinson's disease, and the amyloidoses (69, 71, 72) . Functional defects resulting from missense mutations thought to be patho genic in ADPKD include loss of GPS cleavage (73) and changes in protein folding and trafficking (47) in PC1 and loss of channel activity in PC2 (17) . Our current study used a systematic strategy for categorizing the pathogenic consequences of missense vari ants in PC1 into: (a) variants that do not undergo GPS cleavage; (b) variants that do not traffic properly to cilia despite undergoing GPS cleavage; and (c) variants that are functionally defective despite normal GPS cleavage and trafficking to cilia. For PC2, missense variants can so far be subcategorized into: (a) variants with loss of channel activity but normal trafficking and (b) variants that retain channel activity but do not traffic normally to cilia.
We developed an in vitro assay for trafficking of PC1-CTF and PC1-NTF as well as PC1-FL and found that PC1 expression in cilia was independent of cell type (e.g., LLC-PK 1 cells, IMCD3 cells, and MEFs). PC1-CTF is preferentially biotinylated on the apical surface of live, polarized LLC-PK 1 cells, suggesting that the apical surface and cilia are the primary sites of PC1 surface expression, although there may be some variation by cell type (20) . The preponderance of evidence shows that only the PC1-CTF and PC1-NTF cleavage products can traffic to cilia. We found that at least 2 independent GPS cleavage-deficient mutants did not traffic to cilia, and both were complete lossoffunction of mutants: PC1 L3040H by virtue of its inability to rescue any part of the Pkd1mutant mouse pheno type and PC1
L2811P by virtue of its pathogenicity in human disease. There is some evidence that cleavage at the GPS may not be an absolute requirement for PC1 to enter the secretory pathway. An
), has been reported to acquire endo H resistance (50), however, this mutant also behaves as a hypomorphic partial lossoffunction allele that produces a de novo PC1 cleavage product (73) , thereby raising the possibility that it is not entirely reflective of GPS cleavage-defective mutants in general. Additionally, we showed that at least 2 pathogenic vari ants, PC1 C210G and PC1
V685D
, which do not affect GPS cleavage, also failed to localize to cilia. In aggregate, the data suggest that patho genic point mutations affecting conformational changes, with or without impairing GPS cleavage, can nonetheless impair cilia traf ficking. In the current study, 4 of the 5 PC1 missense mutations we examined failed to traffic to cilia, which poses the hypothesis that a majority of pathogenic point mutations in PC1 have failure to traffic to cilia as a common biologic feature. jci.org
Volume 124 Number 12 December 2014
suggest the possibility that one of the pathogenic effects of trunca tion mutations in PC2 is a markedly decreased steadystate level of PC1-CTF protein, which in turn is critically required for PC1 func tion. The finding that the channeldead pathogenic variant PC2 D511V (17) that traffics to cilia in LLC-PK 1 cells (80) and can rescue the sta bility of PC1-CTF nonetheless results in human ADPKD (56) sug gests that both PC2 interaction with PC1 and PC2 channel activity are independently required for preventing ADPKD. In aggregate, these studies highlight 5 important findings in the pathogenesis of ADPKD: (a) a subset of pathogenic nonsyn onymous substitution mutations results in impaired trafficking of PC1 and PC2 to cilia; (b) mutations that impair GPS cleavage also impair cilia trafficking; (c) ciliatrafficking studies can serve as in vitro assays for PC1 (and PC2) function; (d) the bulk of PC2 resides in the ER without associated PC1 in vivo; (e) truncation mutations in PC2 result in markedly reduced PC1-CTF protein steadystate expression levels. We propose that ciliatrafficking mutant forms of PC1 may be amenable to therapies directed at assisting protein folding with a readout of successful localization to cilia in vitro as the first step to identifying candidate therapeutic agents. In addition, understanding the molecular basis for the sta bilization of PC1-CTF by PC2 interaction could lead to the discov ery of agents that increase steadystate levels of PC1 as a therapy for hypomorphic PC1 variants.
Methods
cDNA constructs, antibodies, and cell culture. The fulllength cDNA of mouse Pkd1 was cloned, sequenced, verified, and modified with NH 2 terminal tripleFLAG and COOHterminal tripleHA epitope tags as described previously (49) . Mutant Pkd1 cDNA constructs were generated on this backbone by sitedirected mutagenesis using the QuikChange kit (Stratagene). All mutations were confirmed by direct sequencing. LLC-PK 1 cells stably expressing WT and mutant Pkd1 constructs were established as described previously (51) . Briefly, cells were transfected with plasmid DNA using Lipofectamine 2000 (Invit rogen) and split at a 1:10 dilution after 24 to 48 hours. Selection with G418 (400-600 μg/ml) was begun after overnight culture. Selected cell clones were characterized by IF cell staining and IB of 50 to 100 μg of protein per sample using antiHA and antiFLAG antibodies.
Rabbit polyclonal antisera for PC2 COOH terminus (YCC2) and NH 2 terminus (YCB9) have been described previously (51) . Other anti bodies used were from the following sources: mouse monoclonal anti Myc (clone 9E10, 1667149; Roche); rabbit polyclonal antiMyc (2272; Cell Signaling Technology); anti-cMyc-conjugated agarose (A7470; SigmaAldrich); rat monoclonal antiHA (clone 3F10, 1867423; Roche); rabbit polyclonal antiHA (715500; Zymed); mouse monoclo nal antiFLAG M2conjugated agarose (A2220; SigmaAldrich); rabbit polyclonal antiFLAG (F7425; SigmaAldrich); mouse monoclonal anti-acetylated αtubulin (T6793; SigmaAldrich); mouse monoclo nal anti-γtubulin (T6557; SigmaAldrich); mouse monoclonal antiβtubulin Cy3 conjugate (C4585; SigmaAldrich); mouse monoclonal anti-HA FITC conjugate (H7411; SigmaAldrich); mouse monoclonal αsubunit of NaK-ATPase clone 6H (gift of Michael Caplan, Yale Uni versity, New Haven, Connecticut, USA); and rabbit polyclonal anti calnexin (SPA-860; Stressgen).
Immunocytochemistry, IP, and IB. IF cell staining was performed as described previously (49, 51) . Briefly, cells grown on coverslips or Cas9 system, may offer similar advantages for future studies. Previous reports of Pkd1-BAC transgenic models showed cystic phenotypes that were the result of high transgene copy numbers (60, 78) and the use of heterologous promoters (61 -BAC model was true to the in vitro data, producing uncleaved PC1 retained in the ER and resulting in a complete lossoffunction allele in vivo. The finding that the entire func tionality of the BAC transgene in multiple founders could be elim inated by a single codon change in only 1 gene, Pkd1, eliminated any possibility that the other genes contained in the BAC had any contribution to the observed phenotypic effects in vivo. Our result with a GPS mutant is somewhat different from that of a knockin mouse model with a mutation in an adjacent codon, Pkd1
), which had postnatal survival up to 2 to 6 weeks with poly cystic kidneys (73) . These phenotypic differences highlight the fact that the specific nature of the genomic alteration and associ ated amino acid substitution is likely to be a key determinant of the degree of functional inactivation of polycystins.
These in vivo models also allowed us to compare the fraction ated tissue distribution of PC1 and PC2. While both proteins are thought to function together in cilia in preventing cyst formation in the kidney, there is ample evidence that they also function inde pendently in various tissues and subcellular locations. PC2 has a role in leftright axis determination, whereas PC1 does not (14, 66) . PC2 is abundantly expressed in the ER, where it has channel activity, but that role appears to be independent of PC1 (17, 18) . Our WT Pkd1 transgenic lines provided direct evidence that PC1 and PC2 distributed in distinct but overlapping density fractions. The majority of cleaved WT PC1 resides in presumed plasma membrane-associated fractions that contained a minute fraction of total tissue PC2. The existence of the bulk of PC2 protein in ERassociated tissue fractions devoid of cleaved PC1 lends strong support to the hypothesis that PC2 has cellular functions in the ER that are independent of PC1. Whether PC2 function independent of PC1 has a role in ADPKD remains to be determined.
Finally, we took advantage of our in vivo and in vitro models to examine the interrelationship between PC1 and PC2 expression. Surprisingly, we found that PC1-CTF required interaction with PC2 to maintain steadystate expression levels. The loss of PC1-CTF in the absence of PC2 was not the result of proteasomal degradation. Although not experimentally verified, there have been reports of a PEST domain in the COOH terminus of PC1 (4), which raises the possibility that the reduced steadystate levels of PC1-CTF in the absence of PC2 are the result of increased degradation by cal pain protease (79) . In this regard, it is notable that PC1 truncation mutants, in which we eliminated the possible PEST domain and the coiledcoil PC2 interaction domain, nonetheless had sufficient stability to traffic to cilia. Interpretation of these findings must be tempered, however, by the fact that these cells highly overex pressed Pkd1 cDNA from a heterologous promoter and cannot be directly compared with a 3copy BAC transgene in the Pkd2 -/-cells. A recent study has suggested that PC1-NTF can exist stably without PC1-CTF, but PC1-CTF is critically required for PC1-NTF traffick ing (50) . In keeping with this, we did not find a profound reduction in PC1-NTF steadystate levels in the absence of PC2. 
L3040H
-BAC mice was prepared using the Maxi Prep Kit (QIAGEN). The BAC was linearized with PISce1, and the digestion product was resolved by fieldinversion gel electropho resis (FIGE) (BioRad). The migration of the highmolecularweight BAC DNA was inferred by a parallel lane stained with ethidium bro mide, the band was excised, and the BAC insert DNA was liberated by digestion with β-agarase I. The eluate was purified using an Ultra freeMC filter column (Millipore) to obtain the linearized BAC DNA ready for pronuclear microinjection at a concentration of 2 to 3 ng/μl. Potential founder animals were screened for the presence of the BAC transgene by PCR primers. Primers directed to the FLAG and HA regions were also used to eliminate founders with only partially inte grated BACs. Genotyping of Pkd1
-BAC included primers flanking the GPS followed by BtsI restriction digestion; the site is lost in the mutant allele. The BAC transgenic lines were produced in (C57BL/6J × SJL/J) F2 mice, and germline transmission was achieved by mating with C57BL6 mice. All strains were subsequently backcrossed at least 4 generations with C57BL6 mice and are therefore expected to be at least 90% C57BL6 congenic.
Quantitation of BAC transgene copy numbers. We have adapted a method for assessing BAC transgene copy numbers using TaqMan based realtime PCR (81) . TaqMan primers were designed to specifi cally amplify either the endogenous WT allele or the transgenespecific allele. Genomic DNA was prepared from mouse livers by phenol chloroform extraction. All samples were run in triplicate on the ABI Prism 7300 System (Applied Biosystems). The 2 primer sets showed highly efficient amplification (R = 0.992 and 0.996, respectively), enabling quantitation of BAC transgene copy numbers.
Planar lipid bilayer measurements. Membrane vesicles enriched in THE ER from LLC-PK 1 porcine kidney cell lines stably expressing WT PC2 or containing the PC2 W414G mutation were isolated by dif ferential centrifugation in the presence of protease inhibitors as pre viously described (17) . These ER vesicles were fused to lipid bilayers containing phosphatidylethanolamine and phosphatidylserine (3:1 w/w; Avanti Polar Lipids) dissolved in decane (40 mg lipid/ml). In experiments using Cs + as the primary current carrier, ER membranes containing PC2 were added to the cis side, which contained 500 mM CsCl, 7 μM CaCl 2 , 10 mM HEPES, and 0. 
-BAC transgenic mice were fractionated on linear iodixanol OptiPrep (SigmaAldrich) gradients as described previously (17) , with minor modifications. Briefly, lung tissue homogenates were prepared using the OptiPrep buffer (AxisShield PoC AS) and loaded onto a freshly made 5%-25% gradient. Samples were centrifuged at 100,000 g in a SW28 rotor for 2 hours. Sixteen ~2ml fractions were collected, and aliquots of each fraction were analyzed by SDS-PAGE followed by IB.
Generation -BAC "paren semipermeable filter inserts were fixed with 2.5% paraformaldehyde and permeabilized with 0.3%Triton X-100 and 0.1%BSA in PBS. Blocking was carried out using 3% BSA, and primary and secondary antibodies were applied at empirically determined dilutions. Cells were examined either by widefield fluorescence (TE2000U; Nikon) with MetaMorph acquisition software or by confocal microscopy (LSM 510; Zeiss). IP experiments were performed as described previously, with minor modifications (49, 51) . Cells were lysed with glycerol lysis buffer (12) , and lysates were precleared by incubation with protein A for 30 minutes, followed by IP starting with 500 to 1,000 μg of protein using antiHA agarose beads (SigmaAldrich) at 4°C overnight. The beads were washed with lysis buffer 5 times, followed by SDS-PAGE on 3% to 8%gradient gels and IB as described previously (49, 51) . Glycosylation analysis and cell-surface biotinylation. Glycosylation analysis was performed as described previously (49, 51) . PC1 was was subjected to IP using either FLAG or HA antibodies and incubated with either endo H, PNGase F, or reaction buffer alone (New England Biolabs) at 37°C for 1 hour followed by IB. Biotinylation of cellsur face proteins was performed using EZ-Link NHS-SS-Biotin (Pierce Biotechnology) as described previously (49, 51) . Nhydroxysuccin imideSSbiotin was applied to living cultured cells stably expressing PC1 for 30 minutes at 4°C. Biotinylated proteins were recovered using streptavidin agarose beads and detected by IB.
BAC modification. The mouse BAC clone RPCI22-287A3 con taining Pkd1 was modified by homologous recombination in E. coli using the method of Lalioti and Heath (57, 58) 
-BAC were generated by sequential BAC modifications to introduce 3 copies each of HA and FLAG epitopes and then the Pkd1-L3040H mutation. In general, for each modification step, approxi mately 1.0 to 1.3kb segments of genomic DNA spanning the sites for the desired variants were amplified by PCR, subcloned into Zero Blunt TOPO (Invitrogen), and sequenced in both directions. Inframe triple HA and tripleFLAG sequences and the variant encoding the L3040H mutation were introduced into the respective targeting vector sub clones and confirmed by sequencing. These targeting constructs were cloned into the shuttle vector PKO4F-Kan (57, 58) containing kanamy cin resistance for positive selection and 2 negative selection cassettes, temperaturesensitive RepAts (permissive at 30°C, nonpermissive at 43°C), and sacB, which blocks growth on sucrose. DH10B bacteria containing the parental BAC clone were made competent by CaCl 2 and transformed with pK04F-Kan containing the targeting sequence and the recA vector pDF25-Tet containing tetracycline resistance. The BAC carries chloramphenicol resistance (cm). Cotransformants were selected by kanamycin (pK04F), tetracycline (pDF25-Tet), and cm (BAC) at 30°C. Cointegrants were selected by growth at 43°C in the presence of kanamycin to select against nonintegrated pKO4F shuttle vector and confirmed by sequencing. Confirmed cointegrants underwent resolution (removal of the reduplicated region) by a second round of transformation with the pDF25-Tet recA plasmid, followed by selection with tetracycline and chloramphenicol at 30°C overnight and a second round of selection by growth on 5% sucrose with cm at 43°C. Single colonies from this final selection step were grown in parallel in cm/Kan/5% sucrose and cm/5% sucrose only. Resolved clones show growth only on cm/5% sucrose. Successfully targeted BAC clones were confirmed by sequencing. jci.org
Statistics. Statistical significance was determined by 2tailed Student's t test, with a P value of less than 0.05 considered statis tically significant. Study approval. All animal studies were reviewed and approved by the IACUC of Yale University.
